We noticed an error in figure 5 in our published manuscript [@B1]. In figure 5 one of the axis in the quantification has been labelled with the wrong marker. Below is a correct version of figure 5.

![**Selective inhibition of PDGFRβ differentially affects tumor pericyte populations in LLC and B16/PDGF-BB tumors.** LLC (**A**, **C**, **E**) and B16/PDGF-BB (**B**, **D**, **F**) tumors were grown in ASKA PDGFRβ mutant mice after treatment with vehicle, 1-NaPP1 or imatinib for 10 consecutive days; sections from tumors were co-immunostained for CD31/podocalyxin and PDGFRβ. PDGFRβ+ pericyte coverage was quantified in LLC (**A**; CD31, green; PDGFRβ, red) and B16/PDGF-BB (**B**; podocalyxin, red; PDGFRβ, green). CD31 and α-SMA were co-immunostained and α-SMA+ pericyte coverage quantified in LLC (**C**) and B16/PDGF-BB (**D**) tumors (CD31, green; α-SMA, red). Podocalyxin or CD31 and NG2 were co-immunostained and NG2+ pericyte coverage quantified in LLC (**E**) and B16/PDGF-BB (**F**) tumors (LLC: CD31, green; NG2, red; B16/PDGF-BB: podocalyxin, red; NG2, green). \>20 field 200x magnification images were scored for each mouse (n=5 or more animals). Scale bar, 50 µm. \*p\<0.05, \*\*p\<0.01 and \*\*\*p\<0.001.](thnov10p7406g001){#F5}

[^1]: \* These authors contributed equally to the study.
